Board additions Detect has recently expanded its governance bench with industry veterans Stefan Willemsen and Jeff Hawkins joining the Board, signaling a strategy shift and potential for strengthened partnerships with c-suite buyers and enterprise customers in diagnostics and women’s health.

Women’s health focus The company positions itself as a leader in women’s health diagnostics with a molecular multiplex platform, presenting cross-sell opportunities to healthcare systems, clinics, and insurers seeking advanced at‑home and point‑of‑care solutions for female-centric conditions.

Strategic partnerships Past collaborations with healthcare providers and institutions indicate a receptivity to joint development or co‑selling arrangements; explore partnerships with hospital networks, telemedicine platforms, and digital health services expanding access to diagnostics for women.

Scale and readiness With 51–200 employees and a mid‑stage revenue profile, Detect appears poised for targeted B2B partnerships and contract manufacturing or distribution deals to scale its multiplex platform for broader clinical deployment and at‑home testing channels.

Industry credibility Participation in high‑profile industry conferences and a leadership team with deep diagnostics experience positions Detect to engage enterprise buyers, government or defense‑adjacent opportunities, and large health systems seeking innovative, rapid diagnostics solutions.